Rutgers University Study of the Genetics of Breast Cancer.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRutgers, The State University of New Jersey
About this trial
The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
age 18 years or older
currently living in the United States
able to understand and follow written instructions in English
have access to the internet and a computer, laptop, tablet or smart phone
Disqualifiers
Not able to meet or fulfill any of the inclusion criteria
Trial population
The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had breast cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Saliva sample
GeneticSaliva sample is sent via prepaid US Mail for DNA extraction
Health Surveys
Other interventionHealth surveys are filled out online in the study portal.
Treatment groups
25,000 Participants
are divided into 2 treatment groupsGroup A: Breast Cancer Cases2 interventions
Group B: Breast Cancer Controls2 interventions
Trial outcomes
Primary outcomes
1
Genetic risk variants associated with breast cancer
Genetic factors will be measured through whole exome sequencing along with genotyping of common variants, and then correlated with breast cancer and breast cancer subtype.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Rutgers, The State University of New Jersey
Lead sponsor
Regeneron Pharmaceuticals
Collaborator
Source ClinicalTrials.gov